An Elevated Value of High Mobility Group Box 1 is a Potential Marker for Poor Response to High-Dose of Intravenous Immunoglobulin Treatment in Patients With Kawasaki Syndrome | Zendy

Taisuke Eguchi | Zendy; Yuichi Nomura | Zendy; Teruto Hashiguchi | Zendy; Kiminori Masuda | Zendy; Michiko Arata | Zendy; Daisuke Hazeki | Zendy; Kentaro Ueno | Zendy; Junichiro Nishi | Zendy; Yoshifumi Kawano | Zendy; Ikuro Maruyama | Zendy

Open Access

An Elevated Value of High Mobility Group Box 1 is a Potential Marker for Poor Response to High-Dose of Intravenous Immunoglobulin Treatment in Patients With Kawasaki Syndrome

Author(s) -

Taisuke Eguchi,

Yuichi Nomura,

Teruto Hashiguchi,

Kiminori Masuda,

Michiko Arata,

Daisuke Hazeki,

Kentaro Ueno,

Junichiro Nishi,

Yoshifumi Kawano,

Ikuro Maruyama

Publication year - 2009

Publication title -

the pediatric infectious disease journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.028

H-Index - 140

eISSN - 1532-0987

pISSN - 0891-3668

DOI - 10.1097/inf.0b013e31818ffe60

Subject(s) - medicine , hmgb1 , kawasaki disease , lactate dehydrogenase , antibody , gastroenterology , receiver operating characteristic , white blood cell , immunology , inflammation , biochemistry , chemistry , artery , enzyme

We examined the serum values of high mobility group box 1 (HMGB1) in 36 patients with Kawasaki syndrome (KS) (29 responders and 7 poor-responders to initial intravenous immunoglobulin treatment). A mean value of HMGB1 of poor-responders was significantly elevated compared with those of responders (P = 0.0042). Among the 6 factors showing significant differences between responders and poor-responders including HMGB1 (admission illness day, white blood cell counts, C-reactive protein, aspartate aminotransferase, lactate dehydrogenase), values of HMGB1 showed the widest area under the receiver operating characteristic curve. In conclusion, an elevated HMGB1 value could be a potential marker for poor-responders.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research